What do systematic reviews say?

PAE vs sham

• Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 80 participants
  Moderate

Transurethral microwave thermotherapy vs transurethral resection of the prostate

• Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 136 participants
  Moderate

Transurethral microwave thermotherapy vs sham

• Transurethral microwave thermotherapy for the treatment of lower urinary tract symptoms in men with benign prostatic… 2021 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 347 participants
  Low

Convective radiofrequency water vapour thermal therapy vs sham

• Convective radiofrequency water vapour thermal therapy for lower urinary tract symptoms in men with benign prostatic… 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 195 participants
  Moderate

PAE vs TURP

• Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 300 participants
  Low

Serenoa repens vs placebo or no intervention

Serenoa repens showed no clear difference in quality of lifeMeasured by IPSS‐QoL score (range 0 to 6) compared with placebo or no intervention (high certainty).

• Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 1001 participants
  High

Serenoa repens in combination with other phytotherapy vs placebo or no intervention

• Serenoa repens for the treatment of lower urinary tract symptoms due to benign prostatic enlargement 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 265 participants
  Very low

PAE vs TURP

• Prostatic arterial embolization for the treatment of lower urinary tract symptoms in men with benign prostatic… 2022 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 176 participants
  Low

PUL vs sham

• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 206 participants
  Moderate

PUL vs TURP

• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 72 participants
  Low
• Prostatic urethral lift for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 69 participants
  Low

Aquablation vs transurethral resection of the prostate

• Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia 2019 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 174 participants
  Low

Naftopidil vs propiverine (anticholinergic)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 37 participants
  Low

Naftopidil vs Eviprostat (phytotherapy)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Moderate

Naftopidil vs tamsulosin

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  11 studies · 878 participants
  Low

Naftopidil vs silodosin (alpha‐blocker)

• Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  5 studies · 652 participants
  Low

Pembrolizumab vs chemotherapy alone

Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).

• Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
  MD 9.05 [4.61, 13.5]
  1 study · 519 participants
  Low